ReviewBiosensors2022
Type I Photosensitizers Based on Aggregation-Induced Emission: A Rising Star in Photodynamic Therapy.
Review in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Aptamer-functionalized aggregation-induced emission micelles for integrated detection and photodegradation of lipopolysaccharides.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Natural Photosensitizers in Cancer Therapy: A Chemo-Biodiversity Perspective on Light-Activated Natural Compounds.Chemistry & biodiversity · 2026Review
- Targeting Intratumoral Bacteria for Enhanced Tumor Suppression with Nano-Based Therapeutics: A Scoping Review.Pharmaceutics · 2026Review
- Review
- An AIE-active type I/II photosensitizer with mitochondria-to-nuclei cascade targeting for highly efficient photodynamic cancer therapy.Materials today. Bio · 2025Article
- Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation.Nanomedicine (London, England) · 2025Review
- Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update.Microorganisms · 2025Review
- Advancements in Antibacterial Therapy: Feature Papers.Microorganisms · 2025Review
- Boosting Hydroxyl Radical Generation with Nitrogen Vacancy-Modified Carbon Nitride for Triggering Dual Damage of Cancer Nucleus DNA-Mitochondria against Hypoxic Tumors.International journal of nanomedicine · 2025Article
- One Change, Many Benefits: A Glycine-Modified Bacteriochlorin with NIR Absorption and a Type I Photochemical Mechanism for Versatile Photodynamic Therapy.International journal of molecular sciences · 2024Article
- DHTPY-Cu@ZOL-Enhanced Photodynamic Therapy: A Strategic Platform for Advanced Treatment of Drug-Resistant Bacterial Wound Infections.International journal of nanomedicine · 2024Article
- Intricate subcellular journey of nanoparticles to the enigmatic domains of endoplasmic reticulum.Drug delivery · 2023Review
- A Photochemical Study of Photo-Induced Electron Transfer from DNAs to a Cationic Phthalocyanine Derivative.Journal of fluorescence · 2023Article
- The Use of Photodynamic Therapy for Head, Neck, and Brain Diseases.International journal of molecular sciences · 2023Review
- Synthesis and properties of novel type I photosensitizer polycyclic amide.Nanoscale advances · 2023Article
- Enzyme-Responsive Double-Locked Photodynamic Molecular Beacon for Targeted Photodynamic Anticancer Therapy.Journal of the American Chemical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Photodynamic therapy (PDT), emerging as a minimally invasive therapeutic modality with precise controllability and high spatiotemporal accuracy, has earned significant advancements in the field of cancer and other non-cancerous diseases treatment. Thereinto, type I PDT represents an irreplaceable and meritorious part in contributing to these delightful achievements since its distinctive hypoxia tolerance can perfectly compensate for the high oxygen-dependent type II PDT, particularly in hypoxic tissues. Regarding the diverse type I photosensitizers (PSs) that light up type I PDT, aggregation-induced emission (AIE)-active type I PSs are currently arousing great research interest owing to their distinguished AIE and aggregation-induced generation of reactive oxygen species (AIE-ROS) features. In this review, we offer a comprehensive overview of the cutting-edge advances of novel AIE-active type I PSs by delineating the photophysical and photochemical mechanisms of the type I pathway, summarizing the current molecular design strategies for promoting the type I process, and showcasing current bioapplications, in succession. Notably, the strategies to construct highly efficient type I AIE PSs were elucidated in detail from the two aspects of introducing high electron affinity groups, and enhancing intramolecular charge transfer (ICT) intensity. Lastly, we present a brief conclusion, and a discussion on the current limitations and proposed opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.